Polyphenolic antioxidants are being identified as cancer Introduction preventive agents. Recent studies in our laboratory have identified and defined the cancer preventive and antiSilymarin, a polyphenolic flavonoid isolated from the seeds of carcinogenic potential of a polyphenolic flavonoid milk thistle [Silybum marianum (L.) Gaertn] (1), is composed antioxidant, silymarin (isolated from milk thistle). More mainly of silibinin (or silybin, Figure 1 ) with small amounts of recent studies by us found that these effects of silymarin other silibinin stereoisomers, namely isosilybin, dihydrosilybin, are due to the major active constituent, silibinin, present silydianin and silychristin (2). Silymarin and silibinin are used therein. Here, studies are done in mice to determine clinically in Europe and Asia for the treatment of liver diseases the distribution and conjugate formation of systemically (ref. 3 and references therein). In patients with liver disorders, administered silibinin in liver, lung, stomach, skin, prostate treatment with silymarin or silibinin has been shown to improve and pancreas. Additional studies were then performed to liver function more rapidly than in those receiving placebo assess the effect of orally administered silibinin on phase (4). Another multicenter trial showed that 420 mg daily II enzyme activity in liver, lung, stomach, skin and small administration of silymarin for several years resulted in a bowel. For tissue distribution studies, SENCAR mice were significant reduction in the mortality of patients suffering from starved for 24 h, orally fed with silibinin (50 mg/kg dose) alcoholic liver cirrhosis (5). The human population in Europe and killed after 0.5, 1, 2, 3, 4 and 8 h. The desired tissues have used silymarin or silibinin as a liver tonic and current were collected, homogenized and parts of the homogenates research indicates that it can be used in a whole range of liver were extracted with butanol:methanol followed by HPLC and gall bladder conditions, including hepatitis and cirrhosis analysis. The column eluates were detected by UV followed as well as dermatological conditions (6,7). In more recent by electrochemical detection. The remaining homogenates years, silymarin has been marketed in the USA and Europe as were digested with sulfatase and β-glucuronidase followed a dietary supplement. by analysis and quantification. Peak levels of free silibinin
analysis. Control mice were killed 1 h after the vehicle treatment and the desired tissues were removed and stored at -80°C.
Extraction of free and conjugated silibinin from different tissues
Each tissue sample obtained from different silibinin treatment time points was assessed for both free and conjugated forms of silibinin. Briefly, tissues (50-150 mg) were suspended in 3 vol of 50 mM Tris-HCl, pH 7.4, and homogenized thoroughly at room temperature using a Polytron PT-10 homogenizer (VWR Scientific, Plainfield, NJ). Each homogenate was divided into two parts. One part (80% of the total homogenate) was added to an equal and inducing perturbations in cell cycle progression (25-27).
methanol in 100 mM acetate buffer containing 50 mM triethylamine (TEA)
More recently, studies from our laboratory have shown that 
Materials and methods
silibinin. In all cases, therefore, the data shown for conjugated silibinin are after subtraction of free silibinin concentrations.
Animal treatment with silibinin for tissue distribution studies
Animal treatment with silibinin for phase II enzyme studies Six to seven-week-old male SENCAR mice were purchased from the National Cancer Institute (Frederick Cancer Research and Development Center, Six to seven-week-old female SENCAR mice were used in the study and housed in the animal facility as detailed above. The animals were acclimatized Frederick, MD). The animals were housed five per cage at 24 Ϯ 2°C and 50 Ϯ 10% relative humidity and subjected to a 12 h light/12 h dark cycle.
for 1 week before use in the present study and fed a Purina chow diet and water ad libitum. Several different studies in the past have used different They were acclimatized for 1 week before use in the present study and fed a Purina chow diet and water ad libitum. Prior to the study, the dorsal side of doses, modes of administration and solutions/suspensions of silymarin or silibinin in rodent studies (refs 1,3,8-11 and references therein). These include the skin was shaved using electric clippers to facilitate skin homogenization for silibinin extraction. The animals were starved for 24 h prior to dosing and doses from as low as 8 mg/kg/day for 10 days to as high as 1500 mg/kg once; administered i.p., intragastrically, p.o., i.v., etc., and dissolved in Tween were hydrated with 0.5 ml of tap water by intragastric intubation 1 h before administration of silibinin. Each time point had five mice. Silibinin, obtained 80/water, suspended in water, suspended in carboxymethyl cellulose, dissolved in saline or 0.1 N sodium hydroxide, etc. (1, 3, (8) (9) (10) (11) . Based on all these commercially from Sigma Chemical Co. (St Louis, MO), was dissolved as 1.5 mg/ml silibinin in a water-based dosing solution containing 0.9% sodium studies, for the phase II enzyme studies reported here we selected two doses of silibinin, 100 and 200 mg/kg body wt, and administered them by oral chloride (w/v), 3% ethanol (v/v), 1% Tween 80 (v/v) and 6.6 mM sodium hydroxide. To make this solution, silibinin was first completely dissolved in intubation dissolved in 0.2 ml of cottonseed oil. The animals in control groups were administered an equal amount of cottonseed oil only by oral intubation. the desired volume of ethanol and Tween 80 and then diluted with sodium chloride and sodium hydroxide solutions to achieve the final dosing solution Each time point and treatment group had five mice. The animal treatments with the above-mentioned doses of silibinin or cottonseed oil alone were done detailed above. Silibinin (at a dose of 50 mg/kg body wt) was administered orally by feeding needle. A group of five mice was also similarly administered once in the morning every day and 24 h after 3, 7 and 15 days mice in each group were killed and liver, lung, stomach, skin and small bowel were vehicle only and served as a negative control for tissue recovery studies. At different times after silibinin administration, mice were killed and liver, lung, removed and immediately placed in ice-cold 0.1 M phosphate buffer, pH 7.4. Tissues were cleaned properly, minced and homogenized in the same buffer stomach, skin, prostate and pancreas were removed. Each tissue sample was quickly snap frozen in liquid nitrogen and stored at -80°C until further and 100 000 g supernatant fractions were prepared as described earlier (28).
Glutathione S-transferase (GST) activity was determined according to Habig et al. (29) using 1-chloro-2,4-dinitrobenzene (CDNB) as substrate. Quinone reductase (QR) activity was determined as described by Benson et al. (30) using 2,6-dichlorophenol-indophenol (DCP-IP) as electron acceptor. The statistical significance of differences in enzyme activities between cottonseed oil-treated controls and two doses of silibinin-treated experimental groups was analyzed using Student's t-test. Throughout the feeding protocol of silibinin in cottonseed oil or vehicle alone, animals were watched for any apparent signs of toxicity and food and water consumption. No evident change was observed in these mice throughout the experimental protocols (results not shown).
Results

HPLC standardization and linear range of silibinin detection
First we standardized the HPLC conditions and both UV and EC detection sensitivity in the linear range. For these, different amounts of commercially obtained silibinin were dissolved in HPLC grade n-butanol and subjected to HPLC separation under different solvent gradient conditions. As shown in Figure 2A , under the HPLC method and solvent gradient system detailed in Materials and methods we were able to detect commercially obtained silibinin as a single peak by both 270 nm UV absorbance and by EC detection. In both cases, silibinin characteristically showed a retention time of 13.5 min (Figure 2A ). These HPLC profiles of silibinin also show its purity as 100%. Based on these HPLC profiles of silibinin, a linear detection range of silibinin under these conditions was also sought. As shown in Figure 2B , the standard curve for silibinin was linear in the range 10-100 ng in the case of UV detection (r ϭ 0.9999) and 4-120 ng in the case of EC detection (r ϭ 0.9999). Whereas the sensitivity of EC detection was much higher than that of UV detection, EC detection showed a high level of variation in detection limits, possibly because of a small change in room temperature or a change of solvent (data not shown), although OSA and TEA were used in the solvents to improve EC detection sensitivity and stability. Because of this, those tissue extract samples which were found to have a high concentration of silibinin were quantified using UV detection, whereas for samples with a low concentration of silibinin EC quantification was used.
Tissue distribution of silibinin After establishing the above HPLC conditions and linear detection ranges, we next analyzed tissue extract samples using appropriate volumes so that the silibinin levels fell in the linear range of detection. As shown in Figure 3 , in repre- endogenous substances also separated in these tissue extract followed by EC detection as described in Materials and methods. Based on samples, although they did not interfere with silibinin separathe HPLC profiles of different concentrations of silibinin detected by both UV and EC, standard curves were derived using peak area as described in tion and quantification, suggesting that silibinin can be easily samples (Figure 3 ). The recovery of silibinin extracted from six different tissues reported here, using butanol:methanol extraction, was 92 Ϯ 5%.
evident at 30 min in the case of liver, lung, stomach and pancreas and at 60 min for skin and prostate. Other than The tissue distribution time kinetics of both free and conjugated silibinin clearly demonstrate that silibinin is liver, where free silibinin concentration decreased sharply after a peak at 30 min, in all other tissues it was retained for a quickly absorbed after oral administration and has a good bioavailability, at least in the tissues examined in the present much longer time, after which silibinin was eliminated from these tissues exponentially (Figure 4) , with the elimination study (Figures 4 and 5) . The concentrations of both free and conjugated silibinin in the tissues examined reached their half-time (t1 -2 ) values ranging from 57 to 127 min (Table I) .
As shown by the data in Table I , the maximum concentrations maximum levels within 1 h after silibinin administration. In the time-response curves the peak levels of free silibinin were of free silibinin in these tissues were 8.8 Ϯ 1.6, 4.3 Ϯ 0.8, pancreas ( Figure 5 ). After their peak levels, these conjugates
Tissue homogenates were prepared, free silibinin was extracted using butanol:methanol and the tissue extracts were subjected to reversed phase of silibinin were eliminated from these tissues in an HPLC as detailed in Materials and methods. The peak area for silibinin was exponential manner ( Figure 5 ), with the t1 -2 values ranging from analyzed for quantification. In each case, the data points shown are means 45 to 94 min (Table I ). The maximum tissue levels of sulfate Ϯ SD of five independent mice; each sample was analyzed by HPLC twice.
and β-glucuronidate conjugates of silibinin were found to be 5.7 Ϯ 0.7, 2.8 Ϯ 0.7, 270 Ϯ 49, 4.3 Ϯ 0.4, 6.1 Ϯ 1.7 and silibinin on both GST and QR enzyme activities. As shown 10.6 Ϯ 1.5 µg/g tissue for liver, lung, stomach, skin, prostate in Table II , silibinin administration resulted in a moderate to and pancreas, respectively (Table I ). The data summarized in highly significant increase in both GST and QR activities in Table I also show that in the case of liver and lung the levels all the tissues examined in both a dose-and time-dependent of free silibinin were higher than conjugated silibinin and that manner. In the case of GST activity, compared with vehiclethe t1 -2 values of free silibinin in these two tissues were shorter treated controls, treatment with 100 and 200 mg/kg doses of than that for conjugated silibinin. Conversely, the levels of silibinin for 3, 7 and 15 days resulted in 8-110 and 10-140% conjugated silibinin were higher than free silibinin in stomach, increases (P Ͻ 0.1-0.001, Student's t-test) in enzyme activity. skin, prostate and pancreas, but the t1 -2 values of conjugated
The observed increase in GST activity was maximum in small silibinin in these four tissues were shorter than that for free bowel at both the doses employed in the study and accounted silibinin (Table I) .
for the 110 and 140% increases (P Ͻ 0.001, Student's t-test) Enhancement of phase II enzyme activities by silibinin over control for the 100 and 200 mg/kg doses, respectively, after 15 days of treatment (Table II) . In liver, lung, stomach The phase II enzymes GST and QR play an important role in detoxification of carcinogens and their metabolites and, and skin the increases in GST activity were comparable in a dose-dependent manner, specifically after 15 days of treatment therefore, are important components of the tumorigenesis process (31,32). Several studies have shown that cancer chemo- (Table II) . Unlike GST activity, compared with vehicle-treated controls, the maximum increases in QR activity (58 and 74%, preventive agents enhance phase II enzyme activities as one of their mechanisms of action (33-36). Based on the cancer P Ͻ 0.001, Student's t-test) was observed in skin at both the 100 and 200 mg/kg dose of silibinin after 15 days treatment chemopreventive and anticarcinogenic effects of silymarin reported by us (21-27) and the results of the present study (Table II) . In general, the increases in QR activity in all the tissues examined, liver, lung, stomach, small bowel and skin, showing the tissue distribution of both free and conjugated silibinin following its systemic administration in mice, studies
were not as profound as GST activity (Table II) . Furthermore, whereas the observed effects of silibinin on the enhancement were also performed to assess the effect of orally administered
Discussion
The major findings in the present study are: (i) standardization of the HPLC method and development of an HPLC system to extract, analyze and quantify the cancer chemopreventive agent silibinin in different biological samples; (ii) that systemic administration of silibinin in mice results in a rapid tissue distribution of both free and conjugated silibinin in the different tissues examined; (iii) that orally administered silibinin in mice results in a significant induction of the phase II enzymes GST and QR in different tissues. The tissue levels of and increase in phase II enzyme activity induced by silibinin were clearly evident in skin and prostate, where silymarin has been reported by us to be a strong cancer preventive and anticarcinogenic agent (22) (23) (24) 27 ). These results convincingly suggest the presence of silibinin in the target organs to exert its cancer inhibitory effect and form the basis for more detailed studies in the future to evaluate the cancer preventive and interventive effects of silibinin, the major active constituent in silymarin, in experimental models of carcinogenesis representing different organ sites.
The use of reversed phase HPLC has been extensively employed in the separation of polyphenolic antioxidants similar to silibinin (37) (38) (39) . Using this system, earlier studies from our laboratory and by others have separated and quantified different polyphenols present in green and black tea (37, 38) . More recently, reversed phase HPLC equipped with an EC detector has been used to identify and quantify tea catechins in human blood, urine, saliva and other tissues (39). Corroborative of these studies, in the present study, using an analytical HPLC system equipped with both UV and EC detectors, we were able to detect silibinin and quantify it in small (ng range) amounts in a linear range. The detection limit for silibinin by the HPLC system used here was comparable with that reported following its systemic administration to SENCAR mice. At the indicated time points after silibinin treatment at 50 mg/kg dose, animals were killed recently for silibinin quantification from human plasma (40) . and the desired tissues were removed. Tissue homogenates were prepared, The observed tissue levels of both free and conjugated silibinin digested with sulfatase and β-glucuronidase, silibinin was extracted using in liver, lung, stomach, skin, prostate and pancreas as early butanol:methanol and the extracts were subjected to reversed phase HPLC as 30 min following intragastric administration suggest that as described in Materials and methods. The peak area for silibinin was analyzed for quantification. In each case, the data points shown are means silibinin is rapidly absorbed from the stomach and shows a rapid Ϯ SD of five independent mice; each sample was analyzed by HPLC twice.
tissue distribution. The rapid absorption and biodistribution of free and conjugated silibinin in different tissues in mice, as reported in this study, is consistent with human studies reported summarized in Table I needed in rodents to assess the absorption, tissue distribution, metabolism and excretion of systemically administered of QR activity were both dose-and time-dependent, only a silibinin. moderate increase in enzyme activity was evident following
During the tumor initiation stage of multistage chemical 3 and 7 days of silibinin treatment at both the 100 and 200 mg/kg doses (Table II) .
carcinogenesis, chemical carcinogens are metabolized by the cytochrome P450 and epoxide hydrolase system to the ultimate carcinogenesis and the mechanisms involved in them and to assess and identify cancer preventive agents (32). Utilizing carcinogenic metabolite that binds to DNA in the target cells, causing genetic alterations followed by tumor initiation (43, 44) . this model, classical biochemical and DNA adduct formation studies have established the role of: cytochrome P450, epoxide The collective action of phase II enzymes such as GST and QR is to afford protection against the adverse effects of hydrolase, phase II enzymes and DNA adduct formation in tumor initiation; induction of edema, hyperplasia, inflammareactive metabolites of procarcinogens (43,44). However, a decrease in phase II and antioxidant enzymes, following tion, cyclooxygenase, lipoxygenase, ornithine decarboxylase, a strong oxidative stress condition, etc. in tumor promotion; exposure to carcinogens and/or tumor promoters, reduces the protective ability of these enzymes against cell damage by several additional genetic and epigenetic alterations and oxidative stress in tumor progression (32,43-46). However, carcinogens and/or their metabolites (43-46). Several cancer chemoprevention studies have shown that following studies in more recent years have focused on genetic alterations, signaling pathways, alterations in cell cycle reguadministration of chemopreventive agents, the levels of phase II enzymes are elevated in various organs of the test animals latory molecules, tumor suppressor genes, transcription factors, etc. as the more defined molecular mechanisms associated (refs 33-36 and references therein). Consistent with these reports, in the present study we observed a moderate to with the tumor initiation, promotion and progression stages of carcinogenesis (32, [47] [48] [49] . Accordingly, cancer prevention statistically significant increase in the activity of the phase II enzymes GST and QR in liver, lung, stomach, skin and small studies identifying and defining the mechanistic aspects of preventive activity have included classical cellular and biobowel of mice orally administered silibinin. The dose-and time-dependent response of silibinin was also clearly evident chemical markers, as well as more detailed molecular events; a few examples are naturally occurring antioxidant green tea in these studies. Together, these data suggest that in addition to several other cellular, biochemical and molecular polyphenolics, genistein, curcumin, quercetin and apigenin (50) (51) (52) (53) (54) (55) (56) (57) . With regard to silymarin, studies over the last 6 years mechanisms of action of silymarin reported by us and others which contribute to its cancer preventive and anticarcinogenic in our laboratory have focused on identifying its preventive and interventive effects in different models and defining effects (21-27), an enhancement in phase II enzyme activity may also be associated with its cancer inhibitory potential.
the cellular, biochemical and molecular mechanisms of such effects. Based on our several published studies and ongoing This suggestion is especially important for the study in which we found that topical application of silymarin for 7 days work, it can be suggested that silymarin and silibinin have multifactorial mechanisms, including strong antioxidant before tumor initiation with 7,12-dimethylbenz[a]anthracene results in a dose-dependent protection against tumor initiation activity, responsible for their cancer preventive and anticarcinogenic activities. in the SENCAR mouse skin initiation-promotion protocol (R.Agarwal et al., unpublished observation).
